FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2020235057> ?p ?o ?g. }

• W2020235057 endingPage "1014" @default.
• W2020235057 startingPage "1009" @default.
• W2020235057 abstract "Although the efficacy of recombinant tissue-type plasminogen activator (rt-PA) in acute myocardial infarction has been demonstrated, little formal dose-ranging information is available. This study examined the use of duteplase, the double-chain rt-PA subsequently used in the Third International Study of Infarct Survival, in a multicenter trial of 267 patients with evolving acute myocardial infarction assigned to receive 1 of 6 weight-adjusted doses. The primary end point was infarct vessel patency after 90 minutes of drug infusion. Patency was defined as Thrombolysis in Myocardial Infarction trial grade 2 or 3 perfusion, and was determined by an independent core laboratory masked to treatment assignment. Patency was present in 48% of patients receiving the lowest dose range and 78% of those receiving the highest, with an association between thrombolytic dose and patency (p = 0.009). The frequency of serious bleeding complications also correlated with the total dose of rt-PA infused (p = 0.003). Bleeding complications were primarily related to instrumentation; blood loss requiring transfusion or otherwise deemed clinically significant occurred in 12% of patients (central nervous system hemorrhage occurred in 1.1%). Thus, higher doses of rt-PA are associated both with increased efficacy and increased risk of serious bleeding complications. Weight-adjusted dosing may provide an optimal risk-benefit ratio for thrombolysis during acute myocardial infarction." @default.
• W2020235057 created "2016-06-24" @default.
• W2020235057 creator A5007343936 @default.
• W2020235057 creator A5014713513 @default.
• W2020235057 creator A5015428271 @default.
• W2020235057 creator A5015497221 @default.
• W2020235057 creator A5016377979 @default.
• W2020235057 creator A5026192383 @default.
• W2020235057 creator A5026402995 @default.
• W2020235057 creator A5029386074 @default.
• W2020235057 creator A5031025425 @default.
• W2020235057 creator A5031923267 @default.
• W2020235057 creator A5039219700 @default.
• W2020235057 creator A5041531882 @default.
• W2020235057 creator A5041973059 @default.
• W2020235057 creator A5045816524 @default.
• W2020235057 creator A5045995808 @default.
• W2020235057 creator A5053609858 @default.
• W2020235057 creator A5073895005 @default.
• W2020235057 creator A5080989104 @default.
• W2020235057 creator A5090737606 @default.
• W2020235057 date "1993-05-01" @default.
• W2020235057 modified "2023-09-27" @default.
• W2020235057 title "Dose-related efficacy and bleeding complications of double-chain tissue plasminogen activator in acute myocardial infarction" @default.
• W2020235057 cites W1533600198 @default.
• W2020235057 cites W1965516055 @default.
• W2020235057 cites W1977288751 @default.
• W2020235057 cites W1994337886 @default.
• W2020235057 cites W1999209170 @default.
• W2020235057 cites W2003818257 @default.
• W2020235057 cites W2009801453 @default.
• W2020235057 cites W2017787887 @default.
• W2020235057 cites W2032492546 @default.
• W2020235057 cites W2041135180 @default.
• W2020235057 cites W2063519653 @default.
• W2020235057 cites W2066927916 @default.
• W2020235057 cites W2091718334 @default.
• W2020235057 cites W2093923223 @default.
• W2020235057 cites W2114742226 @default.
• W2020235057 cites W2118895431 @default.
• W2020235057 cites W2150551942 @default.
• W2020235057 cites W2160883455 @default.
• W2020235057 cites W4251417417 @default.
• W2020235057 doi "https://doi.org/10.1016/0002-9149(93)90564-s" @default.
• W2020235057 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8475860" @default.
• W2020235057 hasPublicationYear "1993" @default.
• W2020235057 type Work @default.
• W2020235057 sameAs 2020235057 @default.
• W2020235057 citedByCount "15" @default.
• W2020235057 countsByYear W20202350572014 @default.
• W2020235057 countsByYear W20202350572015 @default.
• W2020235057 countsByYear W20202350572016 @default.
• W2020235057 countsByYear W20202350572017 @default.
• W2020235057 countsByYear W20202350572022 @default.
• W2020235057 crossrefType "journal-article" @default.
• W2020235057 hasAuthorship W2020235057A5007343936 @default.
• W2020235057 hasAuthorship W2020235057A5014713513 @default.
• W2020235057 hasAuthorship W2020235057A5015428271 @default.
• W2020235057 hasAuthorship W2020235057A5015497221 @default.
• W2020235057 hasAuthorship W2020235057A5016377979 @default.
• W2020235057 hasAuthorship W2020235057A5026192383 @default.
• W2020235057 hasAuthorship W2020235057A5026402995 @default.
• W2020235057 hasAuthorship W2020235057A5029386074 @default.
• W2020235057 hasAuthorship W2020235057A5031025425 @default.
• W2020235057 hasAuthorship W2020235057A5031923267 @default.
• W2020235057 hasAuthorship W2020235057A5039219700 @default.
• W2020235057 hasAuthorship W2020235057A5041531882 @default.
• W2020235057 hasAuthorship W2020235057A5041973059 @default.
• W2020235057 hasAuthorship W2020235057A5045816524 @default.
• W2020235057 hasAuthorship W2020235057A5045995808 @default.
• W2020235057 hasAuthorship W2020235057A5053609858 @default.
• W2020235057 hasAuthorship W2020235057A5073895005 @default.
• W2020235057 hasAuthorship W2020235057A5080989104 @default.
• W2020235057 hasAuthorship W2020235057A5090737606 @default.
• W2020235057 hasConcept C126322002 @default.
• W2020235057 hasConcept C141071460 @default.
• W2020235057 hasConcept C164705383 @default.
• W2020235057 hasConcept C2776572282 @default.
• W2020235057 hasConcept C2777288759 @default.
• W2020235057 hasConcept C2777798775 @default.
• W2020235057 hasConcept C2779581417 @default.
• W2020235057 hasConcept C2779679481 @default.
• W2020235057 hasConcept C2909373784 @default.
• W2020235057 hasConcept C500558357 @default.
• W2020235057 hasConcept C71924100 @default.
• W2020235057 hasConceptScore W2020235057C126322002 @default.
• W2020235057 hasConceptScore W2020235057C141071460 @default.
• W2020235057 hasConceptScore W2020235057C164705383 @default.
• W2020235057 hasConceptScore W2020235057C2776572282 @default.
• W2020235057 hasConceptScore W2020235057C2777288759 @default.
• W2020235057 hasConceptScore W2020235057C2777798775 @default.
• W2020235057 hasConceptScore W2020235057C2779581417 @default.
• W2020235057 hasConceptScore W2020235057C2779679481 @default.
• W2020235057 hasConceptScore W2020235057C2909373784 @default.
• W2020235057 hasConceptScore W2020235057C500558357 @default.
• W2020235057 hasConceptScore W2020235057C71924100 @default.
• W2020235057 hasIssue "12" @default.
• W2020235057 hasLocation W20202350571 @default.

• next